We combined the significantly predictive genes (BCLAF1, TP53, KRAS, and BRAF), the predictive pathways that overlapped with prior functional genomic screens (p53-Dependent G1 DNA Damage Response, Activation of NOXA and translocation to mitochondria, Chaperonin mediated protein folding, RUNX3 regulates CDKN1A transcription, MAP2K and MAPK activation, Scavenging by Class A Receptors, and Integrin cell surface interactions), and baseline features (age, TMB, and tumor type) into a multivariate logistic predictor of immunotherapy response. This evidence concerns the gene KRAS and neoplasm.